Soligenix Inc. (SNGX)
2.10
0.04 (1.94%)
At close: Apr 17, 2025, 3:58 PM
2.10
0.00%
After-hours: Apr 17, 2025, 07:23 PM EDT
1.94% (1D)
| Bid | 1.95 |
| Market Cap | 6.63M |
| Revenue (ttm) | 119.37K |
| Net Income (ttm) | -8.27M |
| EPS (ttm) | -4.98 |
| PE Ratio (ttm) | -0.42 |
| Forward PE | -0.63 |
| Analyst | n/a |
| Ask | 2.14 |
| Volume | 30,332 |
| Avg. Volume (20D) | 88,775 |
| Open | 2.11 |
| Previous Close | 2.06 |
| Day's Range | 2.00 - 2.11 |
| 52-Week Range | 1.68 - 14.83 |
| Beta | 1.85 |
About SNGX
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an ...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 4, 1994
Employees 14
Stock Exchange NASDAQ
Ticker Symbol SNGX
Website https://www.soligenix.com
4 days ago
-9.68%
Soligenix shares are trading lower after the compa...
Unlock content with
Pro Subscription
6 months ago
+28.16%
Soligenix shares are trading higher following a report suggesting that police cordoned off two tracks at a Germany train station due to fears that a traveler was infected by the Marburg virus. The company, in April 2024, announced that the FDA granted it an orphan drug designation for the active ingredient in MarVax.
5 months ago · prismmediawire.com
Soligenix, Inc. to Present at the 2024 ThinkEquity ConferencePrinceton, NJ, October 24, 2024 – PRISM MediaWire – Soligenix, Inc.